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692/100,000, which was 5-10 times higher than the attack rate in the general US population. About 40% of cases occurred before 6 months of age in Apache infants.
Before routine administration of Hib vaccines on the Navajo Reservation, the incidence of invasive Hib diseases in children ^ years of age was 214/100,000 [3] and the incidence of meningitis was 152-173/100,000 [3, 4] . These rates are ~ 10-fold higher than rates in the general US population during the same period. Between July 1988 and May 1990, more than half of the cases occurred before 9 months of age (figure 1) and ~30^ before 6 months.
Immunogenicity of Hib Vaccines
Capsular polysaccharide. We compared the antibody responses to Hib capsular polysaccharide (PRP) vaccine in healthy Apache and white children. [8] Total concentrations of antibody to PRP 1 month after immunization with PRP were ~10 times lower in 24-month-old Apache children than in white children of similar age (table 1) . IgG, IgM, and IgA antibodies were all lower in Apache children.
Hib oligosaccharide-mutant diphtheria toxin conjugate. We randomly assigned 2-month-old Navajo infants to one of three groups. The controls were not immunized against Hib chusetts Public Health Biologic Laboratories, Boston) at 2 months of age (n = 24) [9] . Antibody responses to PRP are shown in table 2. Infants who received BPIG simultaneously with their first dose of HbOC at 2 months had significantly higher antibody concentrations than did the other two groups at 4 months (P < Although it appears that Navajo children were less responsive than white children to HbOC, two factors may have contributed to the differences observed. First, the experimental lots of HbOC may have differed in immunogenicity. A variety of investigational lots of HbOC (lots 5, 8, 9, 10, 11, and 12) were used. We detected no significant lot-to-lot variation in immunogenicity among them [9] , but the power to detect differences was limited.
Second, Navajo children typically received their first immunization at 6 weeks of age, whereas whites received theirs at 2-3 months of age. To examine the effect of this age difference, we evaluated a second cohort of 20 white children who had all received their first immunization before 60 days of age (table 4). The responses of the Navajo infants to two Our studies suggest that Navajo children may be significantly less responsive than white children to PRP, even when this antigen is presented as a covalent conjugate with a protein carrier. However, definitive comparison awaits a study using the same vaccine lot. Despite their delayed response, Navajo infants had antibody responses after three doses of HbOC that were similar to responses of whites and at levels associated with protection from Hib disease.
PRP Methods for serology, microbiology, monitoring of safety and adverse reactions, and data analysis have been described previously [11] .
Enrollment. From 1 July 1988 to 2 August 1990, ~907o of the 9038 births at our study sites were available for recruitment. We could not obtain permission to follow the other 10^. Therefore, few data were collected on those who refused to participate. Among them, the male-to-female ratio did not differ significantly from that among participants. Of the 5190 who were enrolled and received vaccine (n = 2588) or placebo (n = 2602), 4161 (80%) received the second dose of vaccine (n = 2056) or placebo (n = 2105). There were no statistically significant differences between groups in the male-to-female ratio, mean age, ethnic background, number of doses of vaccine or placebo received, interval between doses, or length of follow-up.
Adverse reactions. There were eight deaths in each group. Seizures occurred in nine infants in the vaccine group and seven in the placebo group. Neither seizures nor deaths were clustered by time after immunization. No serious adverse reactions were attributed to the vaccine [ NOTE. Infants who received second dose of vaccine after age specified in protocol were included only in intent-to-treat analysis. Data are from [11] (used with permission). * Lower limit.
ing only children receiving two doses, there was 1 case in the vaccine (n = 2056) and 14 in the placebo group (n = 2105) (P < .001; PEE, 937c; CI, 537o-987o). When the intent-to-treat analysis was modified to include only cases occurring before 15 months there were no cases in the vaccine and 21 in the placebo group (P < .001; PEE, 100%; CI, 8^-100^). When analysis was restricted to children receiving two doses there were no cases in the vaccine and 13 in the placebo group (P < .001; PEE, 100^; CI, 67^-10096).
After the first dose but before the second, no cases occurred in the vaccine group but 8 occurred in the placebo group (P = .005; PEE, 1007c; CI, 417o-1007o). Two were in children who had passed the protocol date for their second dose.
The one case of Hib disease (osteomyelitis) in a vaccine recipient was at 15^2 months of age, 368 days after the second immunization. Levels of antibody to PRP were k0. 125 fig/ml before first vaccination, 2.86 fig/ml just before second  vaccination, 1.49 fig/ml 2 months after second vaccination,  0.14 fig/ml at 1 year of age, and 1.35 fig/ml 42 At the end of the trial, all placebo recipients that could be located (527c, 1347) were given at least one dose of PRP-OMP.
We have continued our surveillance of the entire population on the Navajo Reservation. One additional case of Hib disease occurred in a child who received PRP-OMP in the study at 6 weeks and did not receive a second dose. Hib cellulitis was diagnosed at 7 months of age.
Discussion
Over the past 10 years, we have confirmed the high rates of Hib disease documented 18 years ago in Navajo infants [4] and have documented high rates of Hib disease in the Apache population. In the early 1980s, when Hib vaccines immunogenic in young infants were not available, we evaluated the safety and efficacy of passive immunization with BPIG to prevent Hib disease among Apaches [12] . BPIG was ^0!3d efficacious when administered every 4 months during infancy. Studies of BPIG are summarized elsewhere in this issue [13] .
Although hyperimmune globulin was efficacious in this population, its routine use was not feasible over a long time because of its relatively high cost and the need for repeated injections. Therefore, we evaluated antibody responses to several Hib vaccines in these populations.
Initial studies with unconjugated PRP vaccine demonstrated that the immune responses of Apache children were impaired compared to those of whites [8] . Subsequently, we demonstrated that Navajo children may also have lower immune responses to one of the conjugate vaccines (HbOC) compared with those of white children.
We noted that 6-week-old Navajo infants did not respond to one dose of HbOC. Recently, HbOC has been shown to provide protection after three doses in an open trial in California [19] . HbOC had high levels of efficacy after three doses and possibly after two doses. However, breakthrough cases of Hib disease occurred after a single dose. HbOC does not induce an antibody response after the first dose in most infants [20] . The reasons for the differences between these two conjugate vaccines are not well understood. HbOC appears to present PRP only as a T cell-dependent antigen. Consequently, T cell priming to the mutant diphtheria toxin protein carrier must occur before an antibody response is produced, usually with the second dose. A strong booster response is induced with the third dose [20] .
In contrast, PRP-OMP appears to have properties of both a T cell-dependent and a T cell-independent antigen. The T cell-dependent nature of the vaccine is suggested by booster responses observed in many infants after the second dose [10] and in 18-month-old children who received a primary series of PRP-OMP during infancy [21] . Stein [22] suggested that PRP-OMP also produces direct proliferation of murine lymphocytes and may directly stimulate B cells as described for type 1 T cell-independent antigens. Alternatively, the outer membrane proteins or lipopolysaccharide contained in the OMP carrier may exert adjuvant effects by acting on T cells or macrophages [23] .
Regardless of the mechanism of their action, both Hib conjugate vaccines licensed for use in infants have demonstrated a high level of clinical efficacy and promise to produce a dramatic reduction in the incidence of invasive Hib disease. We suggest that the more rapid serologic response to PRP-OMP and its protective efficacy after a single dose at 2 months offer an important advantage in populations with substantial rates of invasive Hib disease in young infants.
Ultimately, the degree and duration of protection provided by any of the licensed Hib conjugate vaccines in the general US population can be determined only by conducting postmarketing surveys after widespread use. Nevertheless, both PRP-OMP and HbOC have been licensed to immunize 2-month-old infants in the United States. Both have been shown to be >90% efficacious and have the potential to substantially reduce the morbidity and mortality of Hib disease.
